Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of NEHEVA is 0.8% (low). The 2024 annual accounts show negative equity (€-38k) and a net result of €-17k. Equity is shrinking by ~59.8% per year across the filed fiscal years. Its solvency ranks better than 5% of 6596 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 4 annual accounts.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone0.8%
Low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector
−Annual accounts: weaker financial profile
+Young company
+
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Signals
1 signal · with evidenceNegative equity
Equity is negative for financial year 2024: liabilities exceed assets. This is the trigger point of the alarm-bell procedure (Belgian CAC).
View the annual accounts Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.
Filing behaviour
From the deposit records, complete market-wideDeadline passed, not yet counted as missing
The deadline for the year that closed on 31-12-2025 passed on 31-07-2026, 30 days ago. Our copy of the deposit register trails the National Bank (measured: median 14 days, p99 45 days), so we only call this filing missing from 45 days past the deadline.
Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 30-09-2025, 61 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
How we compute the deadline
The year end is derived from 4 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2024, that is 31-07-2025.
Deadline per financial year
| Year closed | Due by | Filed | Variance | Reference |
|---|---|---|---|---|
| 31-12-2025 | 31-07-2026 | nothing on record | not filed | - |
| 31-12-2024 | 31-07-2025 | 30-09-2025 | 61 d late | 2025-00517219 |
| 31-12-2023 | 31-07-2024 | 16-05-2025 | 289 d late | 2025-00097576 |
| 31-12-2022 | 31-07-2023 | 29-08-2023 | 29 d late | 2023-00400063 |
| 31-12-2021 | 31-07-2022 | 31-08-2022 | 31 d late | 2022-20401250 |
Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.
Trust signals
2 signalsMore than 3 years active
Founded in 2021, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Financials
TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€-17k-179.0%
Working capital€-46k-83.7%
Annual accounts & ratios
Source: NBB · 2024Annual accounts filed on 30-09-2025 with the NBB · fiscal year 2024 · micro
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
declining
Equity: declining trend of ~59.8%/year over 4 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2024 · NACE 86, Human health · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -316.0% | 66.7% | |
| Net result | €-17k | €46k | |
| Equity | €-38k | €79k | |
| Gross operating margin | €-14k | €78k | |
| Total assets | €12k | €154k |
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
P5
Stable position over 2021-2024
· n=1851-6596
P5
Stable position over 2021-2024
· n=1851-6590
P5
Stable position over 2021-2024
· n=1851-6596
P5
Stable position over 2021-2024
· n=1852-6598
Describes the position versus peers, not a forecast.
€-14k
-286.2%
21-24
€-17k
-179.0%
21-24
€-15k
-239.6%
21-24
€12k
-3.2%
21-24
€-38k
-77.0%
21-24
€-46k
-83.7%
21-24
€50k
+47.6%
21-24
€47k
+80.9%
21-24
Show 8 other metrics
€3k
-53.9%
21-24
0.01
-51.2%
21-24
0.01
-51.2%
21-24
-316.0%
-82.9%
21-24
-1.32
+16.6%
21-24
43.5%
+57.6%
21-24
-137.5%
-188.3%
21-24
-18.73
-270.8%
21-24
Figures by fiscal year
| Fiscal year | 2024 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | €-14k |
| Net profit | €-17k |
| Cash flow | €-15k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €12k |
| Equity | €-38k |
| Debt | €50k |
| of which ≤ 1y | €47k |
| of which > 1y | €3k |
| Working capital | €-46k |
| Employees (FTE) | - |
Ratios (computed)
| 2024 | |
|---|---|
| Current ratio | 0.01 |
| Quick ratio | 0.01 |
| Working capital ratio | -386.0% |
| Solvency | -316.0% |
| Debt / equity | -1.32 |
| Long-term debt ratio | -0.07 |
| Interest coverage | -18.73 |
| Gross margin | - |
| Net margin | - |
| ROA | -137.5% |
| ROE | 43.5% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Balance-sheet composition 2024
Full annual accounts (19 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €12k |
| Fixed assets | 21/28 | €11k |
| Tangible fixed assets | 22/27 | €11k |
| Current assets | 29/58 | €694 |
| Cash & bank | 54/58 | €694 |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €12k |
| Equity | 10/15 | €-38k |
| Contributions / capital | 10/11 | €10k |
| Accumulated profits (losses) | 14 | €-48k |
| Amounts payable | 17/49 | €50k |
| Amounts payable after one year | 17 | €3k |
| Amounts payable within one year | 42/48 | €47k |
| Trade debts payable within one year | 44 | €7k |
| Income statement | ||
| Gross operating margin | 9900 | €-14k |
| Operating result | 9901 | €-16k |
| Financial charges | 65 | €762 |
| Result before taxes | 9903 | €-17k |
| Net result for the period | 9904 | €-17k |
| Result to be appropriated | 9905 | €-17k |
This table shows the latest fiscal year. 3 prior years, with figures and ratios, belong to a paid plan.
See plans →
Ratios computed by Checked.
Health barometer
FY 2024 · computed7
/ 100
Critical
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.
Directors
Directors & mandates
1 director3 of this company's 3 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing below: a director who resigned there may therefore still show here as sitting. See the acts under Publications.
Current directors & mandates
-
Current15-03-2024 → present
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Insolvency mandates
No insolvency mandates (liquidators, administrators) on record for this company.
Legal Structure
| NACE primary | Bemiddelingsactiviteiten in verband met geneeskundige, tandheelkundige en andere diensten in verband met de menselijke gezondheid(86970) |
| Legal form | Private limited company(610) |
| Incorporation | 22-06-2021 |
| Status | Active |
| Postal code | 1030 |
Structure & network
Locations & real estate
Registered office
on the map · from the address registerEstablishment units
1 locationNEHEVA
since 20212.320.250.490
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels2
Ground area511 m²
Buildings2
Building footprint437 m²
Volume (LiDAR)6,227 m³
Tallest building23.9 m · ±7 fl.
Real-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
Brussels
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21015A0484/00B004 | Brussels | 334 m² | 1 · 274 m² | 16.1 m · 5 fl. |
| 21015A0492/00M003 | Brussels | 177 m² | 1 · 163 m² | 23.9 m · 7 fl. |
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Publications
Lifecycle & Insolvency Signals
No insolvency signals in the Belgian State Gazette
Belgisch Staatsblad · acts
3 acts Capital history · 1
28-02-2025
v3.2
Address history · 1
03-04-2026
Registered-office move
All acts · 3
updated 4 months ago
2026
03-04-2026 Registered office moved within Bruxelles
- Avenue Reine Elisabeth 54 1030 Bruxelies → Avenue Albert Giraud 24 1030-Schaerbeek
2025
28-02-2025 Transaction in capital or shares
Summary:
v3.2
2021
30-06-2021 Incorporation of a new SRL
Summary:
oprichting
Analysis
Financial profile
5 of 5 axes measured53
/ 100
Mixed profile: strong on profitability, weaker on health.
All 5 axes are computed from data Checked has read.
Health
7
Profitability
100
Solvency
33
Growth
32
Stability
94
Credit advice
verdict per customer and amountSimilar
Similar companies
Same sector and regionBE 0800.981.260 · Elsene
BE 0871.185.902 · Ottignies-Louvain-la-Neuve
BE 1028.915.028 · Sint-Pieters-Woluwe
BE 1030.015.284 · Brussel
BE 1031.575.006 · Mont-Saint-Guibert
We hold no filed accounts for this company, so a size comparison is not possible. These companies share only the sector and the region. We hold annual accounts for 2 of the 34 companies in this sector.
Company registry
Company registry (CBE)
Crossroads BankActivities
Bemiddelingsactiviteiten in verband met geneeskundige, tandheelkundige en andere diensten in verband met de menselijke gezondheid86970
Primary activity highlighted.
Names & trade names
| Legal nameFR | NEHEVA |
Registered office
Albert Giraudlaan 24
1030 Schaarbeek, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.